The FDA has approved Rasonque, a once-daily pill for advanced pancreatic cancer, which has shown to nearly double patient survival rates in clinical trials.
The U.S. Food and Drug Administration (FDA) announced the approval of a new cancer treatment pill, Rasonque, on Wednesday. Manufactured by Revolution Medicines in California, this innovative medication targets the RAS protein, which is responsible for driving 95% of pancreatic adenocarcinoma cases.
Rasonque is designed as an inhibitor for the most common type of pancreatic cancer and is taken once daily. In its press release, the FDA described Rasonque as a “new treatment option for patients with advanced pancreatic cancer,” highlighting that the approval was granted more than six months ahead of the agency’s review deadline.
Acting FDA Commissioner Kyle Diamantas emphasized the significance of this approval, stating, “Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.” He expressed pride in the FDA scientists whose diligent efforts made this milestone possible.
The authorization applies to adults suffering from metastatic pancreatic cancer who have either not responded to at least one prior treatment or are unable to receive certain combination drug therapies. Pancreatic adenocarcinoma is one of the deadliest forms of cancer in the United States, accounting for approximately 95% of the 67,000 annual pancreatic cancer cases reported by the National Cancer Institute.
Despite representing only 3.2% of total cancer diagnoses, pancreatic cancer leads to a disproportionately high number of cancer-related deaths due to its tendency to be diagnosed at advanced stages and its rapid progression.
The approval of Rasonque followed a randomized, open-label trial involving 500 patients with pre-treated metastatic disease. Results indicated that patients taking Rasonque achieved a median overall survival of 13.2 months, nearly double the 6.7-month survival rate observed in the standard chemotherapy control group. “This drug showed unprecedented results in an area of high unmet need,” remarked Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence.
The FDA expedited the drug’s market entry by granting it priority review, orphan drug status, and a breakthrough therapy designation. Additionally, the filing was assessed under the FDA commissioner’s National Priority Voucher pilot program, which aims to accelerate access to critical public health treatments.
Before the official approval, the agency issued a “safe to proceed” letter in May, which allowed for an expanded access protocol enabling patients to receive the drug prior to its final approval.
Safety profiles for Rasonque indicate that the most common adverse events associated with the drug include rash, diarrhea, mouth sores (stomatitis), nausea, fatigue, vomiting, abdominal pain, fluid retention (edema), reduced appetite, and bleeding (hemorrhage).
Dr. Anna Berkenblit, chief scientific and medical officer of the Pancreatic Cancer Action Network (PanCAN), described the approval as a landmark achievement, stating, “Today’s landmark approval is the most significant advance we have seen in the fight against pancreatic cancer, a devastating disease. I believe this drug will transform how pancreatic cancer is treated, giving people the opportunity for more time with loved ones, the possibility of a better quality of life, and optimism that continued research may lead to even greater advances.”
This groundbreaking development represents a significant step forward in the ongoing battle against one of the most challenging forms of cancer, offering hope to patients and their families.
According to Fox News, Rasonque’s approval marks a pivotal moment in oncology, particularly for those affected by pancreatic cancer.